United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - glycine (unii: te7660xo1c) (glycine - unii:te7660xo1c) - glycine 1.5 g in 100 ml - 1.5% glycine irrigation, usp is indicated for use as a urologic irrigating fluid with endoscopic instruments during transurethral procedures requiring distension, irrigation, and lavage of the urinary bladder. it may be used for lavage of an indwelling catheter to maintain patency. anuria.

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - glycine (unii: te7660xo1c) (glycine - unii:te7660xo1c) - glycine 1.5 g in 100 ml - 1.5% glycine irrigation usp is indicated as an irrigant during transurethral prostatic or bladder surgery. 1.5% glycine irrigation usp is not for injection. it is contraindicated in patients with anuria.

United States - English - NLM (National Library of Medicine)

hospira, inc. - glycine (unii: te7660xo1c) (glycine - unii:te7660xo1c) - glycine 1.5 g in 100 ml - 1.5% glycine irrigation, usp is indicated for use as irrigating fluid during transurethral prostatic resection and other transurethral surgical procedures. not for injection by usual parenteral routes. do not use in patients with anuria.

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - glycine (unii: te7660xo1c) (glycine - unii:te7660xo1c) - glycine 1.5 g in 100 ml - 1.5% glycine irrigation usp is indicated as an irrigant during transurethral prostatic or bladder surgery. 1.5% glycine irrigation usp is not for injection. it is contraindicated in patients with anuria.

United States - English - NLM (National Library of Medicine)

icu medical inc. - glycine (unii: te7660xo1c) (glycine - unii:te7660xo1c) - 1.5% glycine irrigation, usp is indicated for use as irrigating fluid during transurethral prostatic resection and other transurethral surgical procedures. not for injection by usual parenteral routes. do not use in patients with anuria.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - glycine - unknown - glycine amino acid-glycine active 0.0 - active constituent

Canada - English - Health Canada

icu medical canada inc - glycine - solution - 15mg - glycine 15mg - irrigating solutions

Canada - English - Health Canada

baxter corporation - glycine - liquid - 1.5g - glycine 1.5g - irrigating solutions

Canada - English - Health Canada

b. braun medical inc - glycine - liquid - 1.5% - glycine 1.5% - irrigating solutions

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - isoleucine 0.69 g in 100 ml - parenteral nutrition with 10% freamine® iii (amino acid injection) is indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric patients where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of nonprotein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. see warnings, precautions, pediatric use , and dosage and administration. central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted patients, or those requiring long-term